Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00368030 · ClinicalTrials.gov registry record · Phase 3
A Study of Eszopiclone in Subjects With Insomnia Related to Major Depressive Disorder
A Phase 3 study of Insomnia and Depressive Disorder, Major, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 545
- Enrollment target
- 20
- Study locations
NCT00368030 is a Phase 3 study of Insomnia and Depressive Disorder, Major that has completed, run by Sumitomo Pharma America. The registered enrollment target is 545 participants, above the 167-participant average among 151 other Insomnia trials with a reported enrollment target (226% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT00368030, a Phase 3 study of Insomnia and Depressive Disorder, Major, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 545 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate subjective sleep efficacy in subjects with insomnia related to major depressive disorder.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Eszopiclone
Study Locations (20)
California
- - Garden Grove
- - Irvine
- - Northridge
- - Riverside
- - San Diego
Florida
- - Jacksonville
- - Miami
- - Miami Beach
- - North Miami
- - St. Petersburg
Georgia
- - Atlanta
- - Augusta
- - Decatur
- - Smyrna
Arizona
- - Peoria
- - Tucson
Alabama
- - Birmingham
Arkansas
- - Fayetteville
Colorado
- - Wheat Ridge
Connecticut
- - New Britian
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 545 participants |
| Start Date | 2004-01 |
| Est. Completion | 2004-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00368030
The ClinicalTrials.gov registry entry for NCT00368030 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 545 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 167-participant average among 151 other Insomnia trials with a reported enrollment target (226% higher). The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Insomnia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00368030 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT00368030 about?
NCT00368030 is a clinical study titled "A Study of Eszopiclone in Subjects With Insomnia Related to Major Depressive Disorder". The purpose of this study is to evaluate subjective sleep efficacy in subjects with insomnia related to major depressive disorder.
What is the current status of trial NCT00368030?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 545 participants. The study started on 2004-01. Estimated completion is 2004-10.
What conditions does trial NCT00368030 study?
This clinical trial studies the following conditions: Insomnia, Depressive Disorder, Major.
What interventions are being tested in trial NCT00368030?
The interventions under investigation include: Placebo (OTHER), Eszopiclone (DRUG).
Who is sponsoring clinical trial NCT00368030?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00368030 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Insomnia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)
RECRUITING · Phase 3
-
National Adaptive Trial for PTSD Related Insomnia
ACTIVE NOT RECRUITING · Phase 3
-
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
COMPLETED · Phase 3
-
Short and Long-Term Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis
COMPLETED · Phase 3
-
Registry to Collect Information on Pregnancy, Neonatal, and Infant Outcomes in Pregnant Women Exposed to QUVIVIQ®
RECRUITING
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.